The New York Stem Cell Foundation (NYSCF) Research Institute and the Charcot-Marie-Tooth Association (CMTA) in June announced the stem cell lines resulting from their collaboration, which began in 2014, are now available to academic and commercial investigators around the world through the NYSCF Repository.
The CMTA coordinated 19 patients with a number of CMT diseases who provided fibroblasts to NYSCF scientists, who induced pluripotent stem cell lines using the foundation’s automated Global Stem Cell Array.
Eleven lines are currently available; the remaining eight lines are undergoing reprogramming.
The stem cell lines available are the largest collection of lines for a variety of neuropathy disorders of known genetic causation, according to a release from the organizations.
Visit nyscf.org/repository to order stem cell lines.